A GLOBAL, PATIENT-LED EFFORT TO MEASURE AND IMPROVE ECZEMA CARE AROUND THE WORLD
First of its Kind Collaboration Uses Data-Driven Approach to Evaluate and Compare Health Systems in 13 Countries
Led by patients, driven by data
Thirteen patient organizations from thirteen countries have joined together to form the Global Patient Initiative to Improve Eczema Care (GPIIEC). The initiative is a global collaboration to establish a common “yardstick” to assess the responsiveness of health systems to the needs of patients and their caregivers. This GPIIEC identified the elements of health care provision that matter most to patients and caregivers and developed indicators with which to measure them across thirteen developed nations (Argentina, Australia, Brazil, Canada, Denmark, France, Germany, Italy, Kenya, Portugal, Spain, United States, and the United Kingdom).
Global Measure Dashboard
The measure dashboard selected by the GPIIEC includes 7 domains related to the experience of living with eczema and the provision of medical care:
Treatment Satisfaction
Medical Care Delivery
Control of Symptoms
Burden of Illness
Patient Education and Training
Quality/Safety
Access to Specialists and Treatments
Within each domain, the GPIIEC selected 1-2 measures that were developed using primary survey data or secondary data sources from each country of interest: Argentina, Australia, Brazil, Canada, Denmark, France, Germany, Italy, Kenya, Portugal, Spain, United States, and the United Kingdom.
“We need patient-centered measures for eczema, similar to those that exist for other chronic diseases, so that we can assess progress and chart a path towards improvement.”
– Melanie Funk, Managing Director with Eczema Support Australia
High Burden and Unmet Medical Needs Among Patients with Eczema and Their Caregiver in 13 Developed Countries
Findings from a comprehensive literature review
The literature scan reviews burden and satisfaction with healthcare and treatments across thirteen countries representing a cross-section of developed nations with disparate health care systems.
The global initiative is supported with funding from Leo Pharma and Sanofi and Regeneron.
